Prader-Willi syndrome (PWS) is a rare genetic condition marked by uncontrolled hunger and complex behavioral and medical ...

** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** Primary Weapons Systems (PWS) ...

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with ...

Prader-Willi syndrome (PWS) is a multisystem disorder with an estimated prevalence in several studied populations of 1/10,000–1/30,000. It is characterized by severe hypotonia with poor suck and ...

VYKAT™ XR diazoxide choline treats hyperphagia in PWS in adults and children 4+. See Important Safety Info at VYKATXR.com.

Soleno Therapeutics SLNO gained 6.3% on Aug. 27 after the FDA accepted the new drug application (NDA) seeking approval for its lead candidate, DCCR (diazoxide choline) extended-release tablets, to ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...

Soleno Therapeutics Inc. (NASDAQ: SLNO) pulled off in a major way its randomized-withdrawal phase III study with DCCR (diazoxide choline) in Prader-Willi syndrome, boosting the shares by $22.37, or ...

Prader-Willi syndrome (PWS) is a rare, complicated condition that affects many parts of your body. It stems from a problem with one of your chromosomes (a strand of DNA that carries your genes). It ...